The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: Real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis

Osteoporosis International

Volumn 25, Issue 1, 2014, Pages 339-347

  Hadji, P ^a   Felsenberg, D ^b   Amling, M ^c   Hofbauer, L C ^d   Kandenwein, J A ^e   Kurth, A ^f  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e ROCHE INNOVATION CENTER MUNICH   (Germany)

^f NONE   (Germany)

Author keywords

Adherence; Alendronate; Ibandronate; Intravenous; Persistence; Postmenopausal osteoporosis

Indexed keywords

ALENDRONIC ACID; IBANDRONIC ACID;

AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOREARM FRACTURE; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SPINE FRACTURE;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ALENDRONATE; ANALGESICS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG UTILIZATION; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; MEDICATION ADHERENCE; MIDDLE AGED; MOTOR ACTIVITY; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; TREATMENT OUTCOME;

EID: 84891880336     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-013-2515-2     Document Type: Article

References (41)

1. National Osteoporosis Foundation (2003) Physician's guide to prevention and treatment of osteoporosis. Excerpta Medica, Belle Mead
2. Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010-2018 (Pubitemid 43867702)
3. Hadji P, Klein S, Gothe H, Häussler B, Kless T, Schmidt T, Steinle T, Verheyen F, Linder R (2013) The epidemiology of osteoporosis - Bone Evaluation Study (BEST): an analysis of routine health insurance data. Dtsch Arztebl Int 110:52-57
4. Ström O, Borgström F, Kanis JA, Compston J, Cooper C, McCloskey EV, Jönsson B (2012) Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 6:59-155
5. Hooven FH, Adachi JD, Adami S, Boonen S, Compston J, Cooper C, Delmas P, Diez-Perez A, Gehlbach S, Greenspan SL, LaCroix A, Lindsay R, Netelenbos JC, Pfeilschifter J, Roux C, Saag KG, Sambrook P, Silverman S, Siris E, Watts NB, Anderson FA Jr (2009) The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int 20:1107-1116
6. Prieto-Alhambra D, Nogues X, Javaid MK, Wyman A, Arden NK, Azagra R, Cooper C, Adachi JD, Boonen S, Chapurlat RD, Compston JE, Gehlbach SH, Greenspan SL, Hooven FH, Netelenbos JC, Pfeilschifter J, Rossini M, Sambrook PN, Silverman S, Siris ES, Watts NB, Díez-Pérez A (2013) An increased rate of falling leads to a rise in fracture risk in postmenopausal women with self-reported osteoarthritis: a prospective multinational cohort study (GLOW). Ann Rheum Dis 72(6):911-7
7. Rizzoli R (2011) Bisphosphonates for post-menopausal osteoporosis: are they all the same? QJM 104:281-300
8. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541 (Pubitemid 26411651)
9. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352 (Pubitemid 29483192)
10. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, Dobbels F, Fargher E, Morrison V, Lewek P, Matyjaszczyk M, Mshelia C, Clyne W, Aronson JK, Urquhart J, ABC Project Team (2012) A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 73:691-705
11. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003-1008 (Pubitemid 40064656)
12. Höer A, Seidlitz C, Gothe H, Schiffhorst G, Olson M, Hadji P, Häussler B (2009) Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis. Patient Prefer Adherence 3:25-30
13. Penning-van Beest FJ, Erkens JA, Olson M, Herings RM (2008) Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 19:511-517
14. Siris ES, Selby PL, Saag KG, Borgström F, Herings RM, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122(2 Suppl):S3-S13
15. Silverman SL, Schousboe JT, Gold DT (2011) Oral bisphosphonate compliance and persistence: a matter of choice? Osteoporos Int 22:21-26
16. Hamilton B, McCoy K, Taggart H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 14:259-262 (Pubitemid 40826240)
17. Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209-216 (Pubitemid 37338146)
18. Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ (2002) Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 24:1871-1886 (Pubitemid 35440956)
19. Thiébaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, Schöter KH (1997) Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 103:298-307 (Pubitemid 27459256)
20. Adami S, Felsenberg D, Christiansen C, Robinson J, Lorenc RS, Mahoney P, Coutant K, Schimmer RC, Delmas PD (2004) Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 34:881-889 (Pubitemid 38581134)
21. Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM (2006) Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 54:1838-1846 (Pubitemid 43877933)
22. Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, Reginster JY, Zaidi M, Felsenberg D, Hughes C, Mairon N, Masanauskaite D, Reid DM, Delmas PD, Recker RR (2008) Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 35:488-497 (Pubitemid 351374427)
23. Bianchi G, Czerwinski E, Kenwright A, Burdeska A, Recker RR, Felsenberg D (2012) Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension. Osteoporos Int 23:1769-1778
24. Feldstein AC, Weycker D, Nichols GA, Oster G, Rosales G, Boardman DL, Perrin N (2009) Effectiveness of bisphosphonate therapy in a community setting. Bone 44:153-159
25. Barrett-Connor E, Wade SW, Do TP, Satram-Hoang S, Stewart R, Gao G, Macarios D (2012) Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US™. Osteoporos Int 23:733-741
26. Hadji P, Minne H, Pfeifer M, Bourgeois P, Fardellone P, Licata A, Devas V, Masanauskaite D, Barrett-Connor E (2008) Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Joint Bone Spine 75:303-310
27. Silverman S, Gold DT (2010) Compliance and persistence with osteoporosis medications: a critical review of the literature. Rev Endocr Metab Disord 11:275-280
28. Gold DT, Martin BC, Frytak JR, Amonkar MM, Cosman F (2007) A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin 23:585-594 (Pubitemid 46456906)
29. Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T (2012) GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 23:223-231
30. Ziller V, Kostev K, Kyvernitakis I, Boeckhoff J, Hadji P (2012) Persistence and compliance of medications used in the treatment of osteoporosis-analysis using a large-scale, representative, longitudinal German database. Int J Clin Pharmacol Ther 50:315-322
31. Seeman E, Compston J, Adachi J, Brandi ML, Cooper C, Dawson-Hughes B, Jönsson B, Pols H, Cramer JA (2007) Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int 18:711-719 (Pubitemid 46684777)
32. Sarrel PM (1999) Improving adherence to hormone replacement therapy with effective patient-physician communication. Am J Obstet Gynecol 180:S337-S340
33. Bauer DC, Black D, Ensrud K, Thompson D, Hochberg M, Nevitt M, Musliner T, Freedholm D (2000) Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 160:517-525 (Pubitemid 30112275)
34. Greenspan S, Field-Munves E, Tonino R, Smith M, Petruschke R, Wang L, Yates J, de Papp AE, Palmisano J (2002) Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 77:1044-1052
35. Eisman JA, Rizzoli R, Roman-Ivorra J, Lipschitz S, Verbruggen N, Gaines KA, Melton ME (2004) Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 20:699-705 (Pubitemid 38685015)
36. Dennison EM, Compston JE, Flahive J, Siris ES, Gehlbach SH, Adachi JD, Boonen S, Chapurlat R, Díez-Pérez A, Anderson FA Jr, Hooven FH, LaCroix AZ, Lindsay R, Netelenbos JC, Pfeilschifter J, Rossini M, Roux C, Saag KG, Sambrook P, Silverman S, Watts NB, Greenspan SL, Premaor M, Cooper C, Investigators GLOW (2012) Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone 50:1288-1293
37. Curtis JR, Xi J, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E (2009) Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med Care 47:334-341
38. Breuil V, Cortet B, Cotté FE, Arnould B, Dias-Barbosa C, Gaudin AF, Regnault A, Roborel de Climens A, Legrand E (2012) Validation of the adherence evaluation of osteoporosis treatment (ADEOS) questionnaire for osteoporotic post-menopausal women. Osteoporos Int 23:445-455
39. Häussler B, Gothe H, Göl D, Glaeske G, Pientka L, Felsenberg D (2007) Epidemiology, treatment and costs of osteoporosis in Germany - the BoneEVA Study. Osteoporos Int 18:77-84 (Pubitemid 44885498)
40. Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922-928 (Pubitemid 44498580)
41. Sunyecz JA, Mucha L, Baser O, Barr CE, Amonkar MM (2008) Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporos Int 19:1421-1429